Phase I Dose-Escalation Trial of 225Ac-J591 in Patients With Metastatic Castration-Resistant Prostate Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Oct 2023 Status changed from active, no longer recruiting to completed.
22 Dec 2022 According to an AIkido Pharma media release, AIkido Pharma has changed its name to Dominari Holdings.
13 Sep 2022 Results (n=80) assessing the real-time tissue biopsies in the setting of mCRPC presents challenges that might be overcome with the use of ctDNA by collecting data from NCT03042468 and NCT03276572, presented at the 47th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com